Skip to main content
PlainMeds

What the label lists and what reports show

Erenumab side effects

Erenumab's FDA label: “The most common adverse reactions in AIMOVIG clinical studies (occurring in at least 3% of treated patients and more often than placebo) are injection site reactions and constipation.” FAERS holds 54,778 reports naming it through July 30, 2026; the reaction reported most often, leaving out the conditions it is used for, product-use terms and outcomes, is accidental exposure to product (10,201 reports).

  • No generic listed

Check it at the source: the erenumab FDA label on DailyMed (effective July 14, 2026); the FDA FAERS public dashboard.

What does the patient leaflet say about side effects?

From the patient leaflet: What are possible side effects of AIMOVIG?

AIMOVIG may cause serious side effects, including: Allergic reactions. Allergic reactions, including rash or swelling can happen after receiving AIMOVIG. This can happen within hours to days after using AIMOVIG. Call your healthcare provider or get emergency medical help right away if you have any of the following symptoms of an allergic reaction: swelling of the face, mouth, tongue, or throat trouble breathing Constipation with serious complications. Severe constipation can happen after receiving AIMOVIG. In some cases, people have been hospitalized or needed surgery. Contact your healthcare provider if you have severe constipation or constipation associated with symptoms such as severe or constant belly pain, vomiting, swelling of belly or bloating. High blood pressure. High blood pressure or worsening of high blood pressure can happen after receiving AIMOVIG. […]

Source: FDA drug label, Amgen, Inc, effective July 14, 2026 (SPL set b998ed05-94b0-47fd-b28f-cddd1e128fd8), via openFDA; the full label on DailyMed

What does the label list?

From the label: adverse reactions

The most common adverse reactions in AIMOVIG clinical studies (occurring in at least 3% of treated patients and more often than placebo) are injection site reactions and constipation.

From the label: adverse reactions, continued

The following serious adverse reactions are described below and elsewhere in the labeling: Hypersensitivity Reactions [see Warnings and Precautions (5.1) ] Constipation with Serious Complications [see Warnings and Precautions (5.2) ] Hypertension [see Warnings and Precautions (5.3) ] Raynaud's Phenomenon [see Warnings and Precautions (5.4) ] The most common adverse reactions in AIMOVIG clinical studies (occurring in at least 3% of treated patients and more often than placebo) are injection site reactions and constipation. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Amgen Medical Information at 1-800-77-AMGEN (1-800-772-6436) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. The safety of AIMOVIG has been evaluated in 2537 patients with migraine who received at least one dose of AIMOVIG, representing 3040.2 patient-years of exposure. Of these, 2271 patients were exposed to 70 mg or 140 mg once monthly for at least 6 months, 1305 patients were exposed for at least 12 months, and 216 patients were exposed through 5 years.

Source: FDA drug label, Amgen, Inc, effective July 14, 2026 (SPL set b998ed05-94b0-47fd-b28f-cddd1e128fd8), via openFDA; the full label on DailyMed

What do FAERS reports show?

54,778 reports list erenumab among the medicines taken, each a report of something that happened, not proof the medicine caused it; 2,964 are coded as a death and 4,458 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is. Of the 19 reactions below, 7 are named by the same term (in US spelling) in the label's adverse reactions, warnings or patient leaflet; a reaction the label does not name may still be there under another word, and a report does not show that the medicine caused it.

Reports received each year

The 25 most reported reactions

  • Accidental Exposure To Product10,201
  • Device Difficult To Use10,107
  • Wrong Technique In Product Usage Process (a use or a product term, not a reaction)9,499
  • Drug Dose Omission By Device (a use or a product term, not a reaction)6,655
  • Migraine (a use or a product term, not a reaction)5,201
  • Drug Ineffective (a use or a product term, not a reaction)4,424
  • Headache3,501
  • Constipation (named in the label)3,184
  • Product Storage Error2,976
  • Injection Site Pain (named in the label)2,895
  • Off Label Use (a use or a product term, not a reaction)2,830
  • Nausea2,480
  • Fatigue2,342
  • Alopecia (named in the label)2,264
  • Pain2,003
  • Therapeutic Product Effect Incomplete (a use or a product term, not a reaction)1,969
  • Dizziness1,928
  • Arthralgia1,712
  • Muscle Spasms (named in the label)1,610
  • Hypoaesthesia1,596
  • Vomiting (named in the label)1,568
  • Rash (named in the label)1,529
  • Weight Increased1,447
  • Hypertension (named in the label)1,401
  • Depression1,376

Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026; reactions as MedDRA preferred terms

What next?

Erenumab: the full record
label, generics, price, shortages, recalls
Side effects hub
the most reported medicines and reactions